vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and RENASANT CORP (RNST). Click either name above to swap in a different company.
RENASANT CORP is the larger business by last-quarter revenue ($273.8M vs $177.4M, roughly 1.5× Pacira BioSciences, Inc.). RENASANT CORP runs the higher net margin — 32.2% vs 1.6%, a 30.6% gap on every dollar of revenue. Over the past eight quarters, RENASANT CORP's revenue compounded faster (29.3% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Renasant Bank is an American regional commercial financial institution based in Tupelo, Mississippi. The bank has more than 280 branches in Alabama, Florida, Georgia, Mississippi, Louisiana, Tennessee, North Carolina and South Carolina. Renasant Bank operates under the parent company Renasant Corporation and is affiliated with Renasant Nation, a platform through which they publish blogs and shows.
PCRX vs RNST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $273.8M |
| Net Profit | $2.9M | $88.2M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | — |
| Net Margin | 1.6% | 32.2% |
| Revenue YoY | 5.0% | — |
| Net Profit YoY | — | 112.5% |
| EPS (diluted) | $0.07 | $0.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $273.8M | ||
| Q4 25 | $196.9M | $278.4M | ||
| Q3 25 | $179.5M | $269.5M | ||
| Q2 25 | $181.1M | $267.2M | ||
| Q1 25 | $168.9M | $170.7M | ||
| Q4 24 | $187.3M | $167.1M | ||
| Q3 24 | $168.6M | $220.3M | ||
| Q2 24 | $178.0M | $163.8M |
| Q1 26 | $2.9M | $88.2M | ||
| Q4 25 | — | $78.9M | ||
| Q3 25 | $5.4M | $59.8M | ||
| Q2 25 | $-4.8M | $1.0M | ||
| Q1 25 | $4.8M | $41.5M | ||
| Q4 24 | — | $44.7M | ||
| Q3 24 | $-143.5M | $72.5M | ||
| Q2 24 | $18.9M | $38.8M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 34.8% | ||
| Q3 25 | 3.5% | 27.9% | ||
| Q2 25 | 4.7% | 1.0% | ||
| Q1 25 | 1.2% | 30.4% | ||
| Q4 24 | 13.2% | 29.8% | ||
| Q3 24 | -82.8% | 44.2% | ||
| Q2 24 | 15.9% | 29.6% |
| Q1 26 | 1.6% | 32.2% | ||
| Q4 25 | — | 28.4% | ||
| Q3 25 | 3.0% | 22.2% | ||
| Q2 25 | -2.7% | 0.4% | ||
| Q1 25 | 2.8% | 24.3% | ||
| Q4 24 | — | 26.8% | ||
| Q3 24 | -85.1% | 32.9% | ||
| Q2 24 | 10.6% | 23.7% |
| Q1 26 | $0.07 | $0.94 | ||
| Q4 25 | $0.05 | $0.78 | ||
| Q3 25 | $0.12 | $0.63 | ||
| Q2 25 | $-0.11 | $0.01 | ||
| Q1 25 | $0.10 | $0.65 | ||
| Q4 24 | $0.38 | $0.70 | ||
| Q3 24 | $-3.11 | $1.18 | ||
| Q2 24 | $0.39 | $0.69 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $1.2B |
| Total DebtLower is stronger | — | $806.2M |
| Stockholders' EquityBook value | $653.9M | $3.9B |
| Total Assets | $1.2B | $27.1B |
| Debt / EquityLower = less leverage | — | 0.21× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $1.2B | ||
| Q4 25 | $238.4M | $1.1B | ||
| Q3 25 | $246.3M | $1.1B | ||
| Q2 25 | $445.9M | $1.4B | ||
| Q1 25 | $493.6M | $1.1B | ||
| Q4 24 | $484.6M | $1.1B | ||
| Q3 24 | $453.8M | $1.3B | ||
| Q2 24 | $404.2M | $851.9M |
| Q1 26 | — | $806.2M | ||
| Q4 25 | $372.2M | $499.8M | ||
| Q3 25 | $376.7M | $558.9M | ||
| Q2 25 | $580.5M | $557.0M | ||
| Q1 25 | $583.4M | $433.3M | ||
| Q4 24 | $585.3M | $430.6M | ||
| Q3 24 | — | $433.2M | ||
| Q2 24 | — | $428.7M |
| Q1 26 | $653.9M | $3.9B | ||
| Q4 25 | $693.1M | $3.9B | ||
| Q3 25 | $727.2M | $3.8B | ||
| Q2 25 | $757.8M | $3.8B | ||
| Q1 25 | $798.5M | $2.7B | ||
| Q4 24 | $778.3M | $2.7B | ||
| Q3 24 | $749.6M | $2.7B | ||
| Q2 24 | $879.3M | $2.4B |
| Q1 26 | $1.2B | $27.1B | ||
| Q4 25 | $1.3B | $26.8B | ||
| Q3 25 | $1.3B | $26.7B | ||
| Q2 25 | $1.5B | $26.6B | ||
| Q1 25 | $1.6B | $18.3B | ||
| Q4 24 | $1.6B | $18.0B | ||
| Q3 24 | $1.5B | $18.0B | ||
| Q2 24 | $1.6B | $17.5B |
| Q1 26 | — | 0.21× | ||
| Q4 25 | 0.54× | 0.13× | ||
| Q3 25 | 0.52× | 0.15× | ||
| Q2 25 | 0.77× | 0.15× | ||
| Q1 25 | 0.73× | 0.16× | ||
| Q4 24 | 0.75× | 0.16× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.18× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RNST
| Net Interest Income | $223.6M | 82% |
| Noninterest Income | $50.3M | 18% |
